,153 By targeting those two tumor-expressed receptors, the bi-specific immunotherapeutic agent resulted in a better outcome for DLBCL patients who expressed CD19 and CD22 heterogeneously than CAR T cells that targeted CD19 only. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.